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AtherosclerosisAtherosclerosis, a chronic inﬂammatory disease of the vessel wall, involves multiple cell types of different or-
igins, and complex interactions and signaling pathways between them. Autocrine and paracrine communica-
tion pathways provided by cytokines, chemokines, growth factors and lipid mediators are central to
atherogenesis. However, it is becoming increasingly recognized that a more direct communication through
both hemichannels and gap junction channels formed by connexins also plays an important role in athero-
sclerosis development. Three main connexins are expressed in cells involved in atherosclerosis: Cx37, Cx40
and Cx43. Cx37 is found in endothelial cells, monocytes/macrophages and platelets, Cx40 is predominantly
an endothelial connexin, and Cx43 is found in a large variety of cells such as smooth muscle cells, resident
and circulating leukocytes (neutrophils, dendritic cells, lymphocytes, activated macrophages, mast cells)
and some endothelial cells. Here, we will systematically review the expression and function of connexins
in cells and processes underlying atherosclerosis. This article is part of a Special Issue entitled: The Commu-
nicating junctions, roles and dysfunctions.
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rights reserved.1. Introduction
Atherosclerosis is amultifactorial inﬂammatory disease of the vessel
wall of medium to large-sized arteries. It is the leading cause of mortal-
ity in industrialized countries, and its incidence is rapidly increasing in
the developing nations [1]. Atherosclerosis is characterized by speciﬁc
158 A. Pfenniger et al. / Biochimica et Biophysica Acta 1828 (2013) 157–166lesions of the intimal layer of arteries, called atheromas, where the tra-
ditional components of a chronic inﬂammatory response such as the ex-
travasation and accumulation of leukocytes, the presence of necrotic
debris, the deposition of extracellular matrix, and the apparition of an-
giogenesis, can all be found [2] (Fig. 1). This disease progresses over
decades. In fact, the earliest atheromatous plaques can be found in
teenagers, and most of the consequences are generally apparentMonocyte adhesion
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Fig. 1. Key aspects of the function of connexins in atherosclerosis development. Top left: Cx3
hemichannels. ATP then acts in an autocrine fashion by binding to its receptors, which ultim
the immunological synapse. Cx43 is expressed by DCs and T lymphocytes and gap junctions
cytes is favored by Cx43-dependent communication. Top right: Cx37 reduces platelet aggreg
gation, presumably through the diffusion of anti-aggregating metabolites (cAMP, cGMP) fr
angiogenesis. Cx37-deﬁcient animals have increased angiogenesis and EC proliferation. The
sition from G1 to S phase of the cell cycle.after the 4th decade of life. Atherosclerosis can thus be viewed as a
model of a slowly progressing inﬂammatory disorder.
Atherosclerosis starts with a dysfunction of the endothelial cells
(ECs) lining an artery, which start to express increased levels of adhe-
sion molecules [2,3]. At the same time, lipid particles, such as low
density lipoprotein (LDL)-cholesterol, accumulate within the vessel
wall and become oxidized. The traditional cardiovascular risk factorsM
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7 inhibits monocyte (mΦ) adhesion to the endothelium by the release of ATP through
ately leads to a reduced adhesiveness of the monocyte. Bottom left: Cx43 is involved in
are present at the outer aspect of the immunological synapse. Activation of T lympho-
ation. Platelets form Cx37 gap junction channels. GJIC between platelets reduces aggre-
om the bulk of the thrombus to newly recruited platelets. Bottom right: Cx37 reduces
presence of Cx37 gap junction channels may reduce proliferation by blocking the tran-
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mote these early steps of atherogenesis. The chemotactic activity of
oxidized lipids (oxLDL) combined with the enhanced expression of
adhesion molecules by ECs leads to the adhesion and diapedesis of
leukocytes such as monocytes, lymphocytes, neutrophils and baso-
phils [4]. OxLDLs become phagocytosed by monocytes differentiated
into macrophages, and the inﬂammation is then perpetuated by the
recruited leukocytes. Lipids and inﬂammatory cells slowly accumu-
late and eventually form a necrotic core. Simultaneously, chemotactic
factors secreted within the neointima also drive the de-differentiation,
migration and proliferation of smoothmuscle cells (SMCs) from the un-
derlying media into the neointima. The cells ultimately form a ﬁbrous
cap sealing off the necrotic core from the lumen. Further progression in-
volves the growth of newly formed vessels within the plaque, which
can promote the arrival of new inﬂammatory cells. The growth of
such a plaque will impinge on the vessel lumen (i.e. cause a stenosis)
which can lead to symptoms if the restriction of bloodﬂow is too severe,
and especially in case of increased demand of blood supply (stable an-
gina pectoris, for instance, when stenosed coronary arteries impair
proper perfusion of the myocardium during exercise). However when
the stability of such a plaque is compromised, i.e.when the balance be-
tween the ﬁbrous elements and inﬂammatory components is lost, the
plaque can rupture. This exposes a highly thrombogenic material to
the blood ﬂow, which then leads to the activation and aggregation of
platelets and to the activation of the coagulation cascade. If the throm-
bus formation is not limited, it can lead to the rapid occlusion of the
vessel, which in turn causes an ischemia of perfused organs (for in-
stance, a myocardial infarction (MI), when a coronary artery is
abruptly occluded).
It is well recognized that atherosclerosis, like most cardiovascular
diseases, arises from interactions between environmental factors and
multiple genes. The heritable component of cardiovascular diseases is
estimated between 40% and 60%, depending on the populations [5]. In
fact, the role of genetic polymorphisms in this disease has been
highlighted by numerous large genome wide studies [6]. Every path-
ophysiological aspect of atherosclerosis could be linked to several ge-
netic polymorphisms. For instance, polymorphisms in genes involved
in lipid metabolism, such as the apolipoproteins (apoB, apoE), have
been frequently associated with coronary artery disease (CAD) and/
or MI [7,8]. Endothelial dysfunction is assumed to be predisposed by
polymorphisms in the endothelial nitric oxide synthase (eNOS),
which were correlated with carotid intima/media thickness and
CAD [9,10]. Similarly, polymorphisms in genes involved in oxidative
stress, inﬂammation, hemostasis, and vascular remodeling could all
be correlated with atherosclerosis-related diseases [6]. Interestingly,
the 1019C>T polymorphism of the human Cx37 gene, which results
in a single amino acid substitution in the regulatory C-terminal re-
gion of this protein (P319S) has repetitively been associated with
atherosclerosis-related diseases such as carotid artery stenosis and
its consequence, stroke, as well as CAD and MI [11–15]. These obser-
vational studies pointed toward a possible implication of connexins
in atherosclerosis development.
Connexins are a homogeneous family of proteins expressed in a
large variety of tissues and known for their assembly into intercellular
channels, called gap junctions [16]. Twenty-one different human con-
nexin genes have been reported so far, each coding for a protein with
4 transmembrane domains, 2 extracellular and one cytoplasmic
loops, a short cytoplasmic N-terminal domain and a longer regulato-
ry C-terminal domain [17]. Connexin proteins are named after their
speciﬁc molecular weight in kDa (for instance, Cx43 has a mobility
of 43 kDa, see http://www.genenames.org/genefamily/gj.php). Six
connexins can oligomerize and form a hemichannel or connexon.
When two cells are closely apposed, connexons from one cell can
dock with their counterparts in the neighboring cell and form a gap
junction channel. Depending on the cell type and the connexin
expressed, connexons can function as hemichannels, providing apathway for transmembrane signaling, whereas gap junction chan-
nels will enable a direct communication pathway between the cyto-
plasm of adjacent cells. Both communication pathways are believed
to be essential for proper cell and tissue homeostasis, and have
been shown to play a major role in a wide variety of biological and
pathological processes.
Atherosclerosis is a chronic inﬂammatory disease with multiple
cellular protagonists, and thus with complex interactions between
several cell types. Most suggested and investigated signaling path-
ways involve autocrine and paracrine communication through cyto-
kines, chemokines, growth factors and their respective receptors.
However, it is now increasingly recognized that a more direct path-
way, such as gap junction intercellular communication (GJIC), also
plays a role in inﬂammatory diseases in general, and atherosclerosis
in particular. Moreover, signaling through connexin hemichannels is
also increasingly described in inﬂammatory disorders. In this review,
we will describe the expression and function of connexins in each cell
type involved in atherosclerosis and, if possible, their implication in
the development of atherosclerosis.
2. Connexins in the pathogenesis of atherosclerosis
2.1. Endothelial cell dysfunction
Endothelial cell dysfunction is regarded as the ﬁrst event in ath-
erosclerosis development. Following exposure to disturbed blood
ﬂow patterns and pro-inﬂammatory or toxic circulating factors such
as encountered in the metabolic syndrome, dyslipidemia, in smokers
or in systemic pro-inﬂammatory states, ECs start to express adhesion
molecules. Simultaneously, the expression and function of eNOS be-
comes altered [18]. Its product, NO, has several vasoprotective effects:
it reduces inﬂammation, leukocyte adhesion, platelet aggregation,
and SMC proliferation and induces endothelium-dependent vasodila-
tion [19]. The hallmark of dysfunctional ECs is a markedly reduced syn-
thesis of NO. Moreover, deleterious reactive oxygen species (ROS) can
be produced by uncoupling of eNOS itself, by the nicotinamide adenine
dinucleotide phosphate (NAPDH) oxidase and by xanthine oxidase, or
by neighboring inﬂammatory cells. These ROS further reduce nitric
oxide (NO) bioavailability by converting it to peroxynitrite and thus
contribute to the phenomenon of endothelial dysfunction. Additionally,
ROS can oxidize eNOS itself, further reducing NO production.
In arteries of a healthy individual, ECs mainly express Cx37 and
Cx40. However, both connexins are lost in the endothelium overlay-
ing atherosclerotic plaques [20]. In addition, Cx43 can be detected
in ECs at speciﬁc regions of arteries [21], such as at branching sites,
which are highly susceptible to atherosclerosis development, and
also at the shoulder regions of plaques [20]. The mechanisms involved
in the modiﬁcation of connexin expression pattern in atherosclerosis
have not been elucidated yet. However, it was suggested that inﬂam-
matory mediators may be involved. In fact, cultured ECs were shown
to lose Cx37 and Cx40 expression after treatment with tumor necrosis
factor (TNF)-α, whereas Cx43 expression was only modestly modi-
ﬁed [22]. It is thus likely that the abundance of pro-inﬂammatory cy-
tokines in an atheroma may cause a reduction in endothelial Cx37
and Cx40 expression. In addition, some cytokines, like interleukin
(IL)-1β, were shown to regulate the function of gap junction channels
and hemichannels in other inﬂammatory systems [23,24]. It is thus
conceivable that connexin function may also be affected by cytokines
in atherosclerosis.
A functional coupling of arterial ECs seems to be important for a
synchronized response of ECs to various agonists. For instance, it
was shown that individual responses to acetylcholine or histamine
are variable in ECs of rat aortic segments [25]. As the histamine recep-
tor H1 is only focally expressed in the endothelium, GJIC is necessary
for a homogeneous increase in cytosolic calcium and subsequent acti-
vation of eNOS following exposure to histamine [26]. An additional
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recently demonstrated. Cx37 is a direct protein partner for this pro-
tein, and a mutual functional regulation between eNOS and Cx37
was demonstrated in ECs [27]. Downregulation of Cx37 caused an in-
crease in NO release, without affecting eNOS expression. Conversely,
short eNOS-mimetic peptides modiﬁed the regulation properties of
Cx37 gap junction channels. Moreover, Cx40-deﬁcient mice have a re-
duced expression of eNOS in ECs and a decreased endothelium-
dependent vasorelaxation [28]. In addition to modiﬁed eNOS function,
dysfunctional ECs express increased amounts of selectins (E-selectin,
P-selectin) and integrins (intercellular adhesion molecule (ICAM)-1,
vascular cell adhesion molecule (VCAM)-1), which promote leukocyte
adhesion to the endothelium and subsequent transmigration into the
intimal space. This increase in adhesion molecules is tightly regulated
in physiological conditions and for instance, VCAM-1 expression is
downregulated by the ecto-nucleotidase CD73on ECs. Here again, inter-
cellular communication seems to be involved in the regulation mecha-
nisms. In fact, endothelial-speciﬁc deletion of Cx40 in atherosusceptible
mice (on an ApoE−/− background) was associated with a reduction in
expression and activity of CD73, as well as a massive increase in
VCAM-1 expression [29]. These mice subsequently developed earlier
and larger atherosclerotic plaques than their control littermates.
A role for endothelial Cx43 in atherosclerosis development is less
clear. Its expression is generally very low or absent in the arterial en-
dothelium of healthy individuals. Cx43 expression was shown to be
increased in the aorta of platelet endothelial cell adhesion molecule
(PECAM)-1 deﬁcient mice, which, when bred in an ApoE−/− back-
ground, developed less atherosclerosis than PECAM-1-expressing
ApoE−/− mice [30]. However, Cx43 may also be increased in regions
subjected to disturbed ﬂow, where increased atherosclerosis devel-
opment is present. Interestingly, inhibition of Cx43-mediated GJIC be-
tween ECs by mimetic peptides decreased adhesion of inﬂammatory
cells [31]. These discrepancies underline the need formore detailed stud-
ies using cell-speciﬁc deletion of Cx43 in the context of atherosclerosis.
It therefore appears that endothelial Cx37 and Cx40 are important
in the maintenance of endothelial quiescence, by favoring a proper
expression and regulation of eNOS, and by inhibiting leukocyte adhe-
sion, whereas the function of endothelial Cx43 is less clear. Thus an
alteration of Cx37 or Cx40 expression could potentially lead to EC
dysfunction, and promote atherosclerosis development.
2.2. Inﬂammatory cell recruitment
2.2.1. Monocytes/macrophages
The combination of adhesion molecules on ECs and release of che-
motactic factors from the vessel wall facilitates monocyte adhesion
and transmigration from the artery lumen to the intima [2]. Mono-
cytes then differentiate into macrophages and phagocyte oxLDL due
to its binding to their scavenger receptors. Lipids progressively accu-
mulate within macrophages, which become foam cells, the hallmark
of atheroma [4]. OxLDL increases the activation of macrophages and
their synthesis of cytokines (such as TNF-α) which further promotes
the recruitment of leukocytes. In addition, macrophages release toxic
ROS that maintain the oxidation of LDL particles. Finally, macro-
phages secrete several proteases that will weaken the newly synthe-
sized ﬁbrous cap, and thus promote plaque rupture. Macrophages can
also act as antigen presenting cells (APCs) and contribute to the im-
mune component of atherogenesis, but this will be discussed in
more detail in the section on dendritic cells (DCs), as they are proto-
typical APCs.
Circulating monocytes express low levels of Cx37 [32], but other
connexins could not be detected. However upon stimulation with a
combination of cytokines (TNF-α and interferon (IFN)-γ) human
bloodmonocytes were shown to express Cx43. It could also be demon-
strated that whereas clusters of nativemonocyteswere not functionally
coupled, Lucifer Yellow could diffuse between cells once they weretreated with TNF-α and IFN-γ [33]. In atherosclerotic plaques, macro-
phages and foam cells were strongly immunoreactive for Cx37 and in
some instances, Cx43 could also be found [20].
The function of Cx43 expression in monocytes/macrophages in ath-
erosclerosis has not been investigated so far. However, Cx43 seems to
be important for macrophage phagocytosis by regulating Ras homolog
gene family, member A (RhoA)-dependent rearrangement of the actin
cytoskeleton [34]. This role was demonstrated for Fc receptor (FcR)-
driven phagocytosis, but one could hypothesize a similar role in phago-
cytosis mediated by other receptors, such as the scavenger receptors.
This could add a novel potential role for Cx43 in atherosclerosis devel-
opment, by favoring uptake of oxLDL by macrophages.
The role for Cx37 in monocytes/macrophages in atherosclerosis is
more evident. As shown in Fig. 1 (top left), hemichannels formed by
this connexin confer an anti-adhesive property to monocytes via the re-
lease of ATP in the extracellular space, which can then have an auto-
crine/paracrine effect on monocytes [32]. In fact, monocytes deﬁcient
for Cx37were shown to adheremore strongly to non-biological surfaces
as well as to a monolayer of ECs. Using adoptive transfers of murine
blood cells, it could be concluded that Cx37-deﬁcient monocytes were
more likely to enter atherosclerotic plaques than Cx37-expressing
cells. These results provided a likely mechanistic explanation to the
atherosusceptible state of Cx37-deﬁcient mice. Interestingly, the afore-
mentioned genetic polymorphism in the human Cx37 gene, which re-
sults in either a proline (major allele) or a serine (minor allele) at
position 319 of the Cx37 protein, appeared to affect cell adhesion. In
fact, cells transfectedwith the 319S isoform of Cx37weremore adhesive
than when the 319P isoform was expressed.
In conclusion, Cx37 expression in monocytes and macrophages
has an anti-atherosclerotic effect by reducing cell adhesion, and the
role of Cx43 in these cells in the context of atherosclerosis is not yet
deﬁned.
2.2.2. Lymphocytes
Although innate immunity incontestably plays a major role in
atherosclerosis, it became evident over the last decade that adaptive
immunity also contributes to the pathogenesis of plaque develop-
ment. T cells are recruited to the intima by similar processes than
monocytes [4]. They are much less numerous than macrophages
within lesions (about 4 to 10 times less in human plaques). Once in
the lesions, they are activated, secrete proatherogenic mediators
and participate in plaque growth. B cells have also been described
in plaques, but they are more abundant in the adventitial layer of ar-
teries. Finally, tertiary lymphoid structures are commonly associated
with advanced atherosclerotic plaques. Through the study of mice
deﬁcient for B or T cells, it has become evident that antigen-speciﬁc
adaptive immune responses contribute to atherosclerosis develop-
ment [35]. B cells may play a protective role, for instance by produc-
ing antibodies directed against oxLDL. However, it was suggested that
speciﬁc subsets of B cells could also favor atherosclerosis development.
Thus, the role of B cells does not appear straightforward. In contrast, T
cells are central protagonists in atherogenesis. Themajority are positive
for the CD4 antigen, though some CD8+ cells can also be found. The
main pathogenic effects of T cells are mediated by a T helper (TH)1 re-
sponse,with high secretion of IFN-γ. However, a role for the TH17 subset
has also been proposed. Regulatory T (Treg) cellsmay also be involved, as
a transfer of forkhead box P3 (Foxp3)+ T cells confers protective effects
against atherosclerosis development in mice.
As with all leukocytes in general, the study of connexins in lym-
phocytes is complex, due to the large panel of different lymphocyte
subsets, the rapid evolution of knowledge in that respect, and the dif-
ﬁculty to properly characterize lymphocytes. Thus, all results should
be interpreted in view of the origin and speciﬁc characteristics of
the cells used in each study.
T lymphocytes express Cx43. Cx40 has also been reported, but in-
consistently, and only in T cells derived from human tonsils [36]. To
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mouse spleen-derived TH0 cells were differentiated into TH1 or TH2.
It appeared that the spleen-derived TH1 cells expressed more Cx43
than TH0 or TH2 [37].
Regarding T cells, two distinct aspects need to be considered: ini-
tial development and further differentiation/activation. A function for
Cx43 in T cell development has been investigated using a mouse
model with T cell-speciﬁc deletion of Cx43, as well as with chimeric
mice lacking Cx43 in all bone marrow-derived cells [38,39]. In both
models, T cell development appeared physiological despite Cx43 de-
letion. Thus, Cx43 expression in T cells does not appear to play a
prominent role in their development.
Regarding T cell activation, a prominent role for Cx43 was recently
described in the T cell–DC antigen-dependent interaction, known as
immunological synapse [40] (Fig. 1 bottom left). Cx43 was shown to
accumulate at the outer aspect of the immunological synapse both
in CD4+ cells and DCs, but only when the T cell receptor (TCR) was
engaged with a speciﬁc major histocompatibility complex class II
(MHC-II): antigen couple. Moreover, this concentration of Cx43 led to
a bidirectional transfer of ﬂuorescent probes, indicating functional gap
junction channels. Absence or blockade of Cx43 by a mimetic peptide
or 18-β-glycyrrhetinic acid reduced the intracellular calcium oscilla-
tions in T cells following antigen recognition, and reduced IFN-γ secre-
tion. Thus, the presence of Cx43 appears to be important for T cell
activation. As a TH1 antigen-speciﬁc response is involved in atherogen-
esis, it is likely that Cx43may participate in the development of this dis-
ease by contributing to the activation of lymphocytes.
Tregs also express Cx43, and several roles for this protein have been
proposed. First, T cell-speciﬁc deletion of Cx43 in mice (CD4-Cre+
Cx43ﬂ/ﬂ) markedly reduced the amount of Treg cells, without affecting
other T cell subsets, as mentioned above [38]. This indicates that Cx43
is essential for the development of Treg cells. The overexpression of
Cx43 in a lymphoblast cell line caused the overexpression of the cru-
cial Treg transcription factor Foxp3, and this effect was lost when the
C-terminal domain of Cx43was truncated. Thus, it seems that Cx43 is
necessary for the differentiation of Treg cells, which may have conse-
quences in the context of atherosclerosis. Second, the formation of
gap junctionswith target T cells may participate in the suppressor func-
tion of Tregs, and as cyclic adenosine monophosphate (cAMP) is known
to mediate that suppressor effect in target cells, it was hypothesized
that its transfer through gap junctions could be involved [41].
B cells at different stages of differentiation were also shown to ex-
press Cx43 [36]. Here again, chimeric mice lacking Cx43 in bone
marrow-derived cells exhibited normal B cell development [39]. Using
various B cell lines, Machtaler and colleagues [42] suggest that Cx43 is
involved in B cell activation and adhesion following the involvement
of the BCR immunological synapse. Splenic B cells from Cx43+/− mice
also appeared to have a slightly reduced adhesion on anti-IgM-coated
surfaces than cells isolated from wild-type mice. Unlike as described
in T lymphocytes, the effect of Cx43 on B cell activation seemed to de-
pend on the presence of the C-terminal domain of Cx43, and not on
intercellular transfer of molecules. As B cells, and mostly their produc-
tion of antibodies derived against plaque antigens, are thought to be
atheroprotective, Cx43-dependent activation of these cells may be ben-
eﬁcial against plaque growth.
In conclusion, the overall effect of Cx43 on lymphocyte participa-
tion in atherosclerosis development is far from being straightforward.
Overall, it participates in the activation and function of most lympho-
cyte subtypes, and could thus both have pro- and anti-atherogenic
functions, depending on the degree of activation of each cell type.
However, speciﬁc studies on lymphocyte connexins in the context
of atherosclerosis remain to be performed.
2.2.3. Dendritic cells
DCs are professional APCs that can present exogenous or endoge-
nous antigens to T cells. There are 2 subtypes of DCs: conventional ormyeloid DCs (mDCs) and plasmacytoid DCs (pDCs). Though much
less abundant than macrophages, both have been detected in athero-
sclerotic plaques, but more consistently in the associated adventitia
and lymphoid tissues. In healthy arteries, mDCs are thought to have
a tolerogenic role by silencing T cells [4]. In the context of atheroscle-
rosis, mDCs can accumulate lipids like macrophages, or become acti-
vated by danger signals (oxLDL and its degradation products) and
thus become activators of T cells [43]. This will lead to increased pro-
duction of proatherogenic cytokines such as IFN-γ and TNF-α. pDCs,
being one of the main sources of class I IFN, were ﬁrst hypothesized
to be proatherogenic as well. However, a recent study demonstrated
that pDCs protect against atherosclerosis by dampening the T cell re-
sponse [44]. The secretion of the tolerogenic molecule indoleamine
2,3-dioxygenase by pDCs was able to suppress T cell proliferation.
Knowledge on connexins in DCs is currently restricted to mDCs,
which also express Cx43. As above-mentioned, a role for Cx43 in
the immunological synapse between T cells and (m)DCs was recently
demonstrated. In addition, GJIC between DCs, or between DCs and
target cells, has also been demonstrated. First, ﬂuorescent markers
can diffuse within clusters of DCs activated by lipopolysaccharide
(LPS) or TNF-α in addition to IFN-γ. Incubation with gap junction
blockers seems to inhibit the induction of the costimulatory mole-
cules CD80 and CD86 [45]. Thus, communication between DCs could
participate in their proper activation and subsequent antigen presen-
tation. Second, a role for connexins in cross-presentation of antigens
has been extensively demonstrated [46–48]. In fact, it was shown
that peptidic antigens can diffuse through gap junctions in DCs. The
receiver DC is able to present this newly acquired peptide on MHC-I
molecules, and thus activate cytotoxic CD8+ T cells. CD8+ cells
have not been extensively investigated in atherosclerosis develop-
ment. However, it was suggested that they may be involved in disease
progression and plaque destabilization [49].
Here again, the function of connexins inDCs in the context of athero-
sclerosis remains hypothetical. Increase of DC activation by gap junc-
tions, and participation in the immunological synapse and in antigen
cross-presentation, could promote atherosclerosis development.
2.2.4. Neutrophils
Neutrophils are important actors of innate immunity and are rap-
idly recruited from the microcirculation to sites of inﬂammation. Less
is known about their contribution to chronic inﬂammation. Recently,
however, a role for neutrophils in macrovascular inﬂammation and in
atherosclerosis has been reported [50–54]. Although neutrophils are
not easily detectable in human and murine atherosclerotic lesions, a
correlation between blood neutrophil counts and size of atheroscle-
rotic plaques has been observed [50,52]. Hypercholesterolemia was
shown to stimulate granulopoiesis and increase neutrophil mobiliza-
tion from the bone marrow. Simultaneously, high cholesterol in-
creases the expression of adhesion molecules by ECs, which when
combined with chemotactic cytokines can then recruit circulating
neutrophils to atherosclerotic lesions [55]. Neutrophil secretory gran-
ules are reservoirs of antimicrobial proteins, proteases, components
of the respiratory burst, as well as of a wide variety of ligands for en-
dothelial membrane receptors, extracellular matrix proteins and sol-
uble mediators of inﬂammation [56,57]. Thus, in addition to their
participation in the initiation of atherosclerosis, the release of pro-
atherosclerotic factors by activated neutrophils may compromise
the stability of ﬁbrous caps [58].
There is circumstantial evidence that neutrophils do express con-
nexins and that gap junctionsmay be established between inﬂammato-
ry cells during the course of inﬂammation [59]. Hence, it was proposed
that unstimulated human neutrophils express the major vascular con-
nexins, namely Cx37, Cx40, and Cx43 [60]. In contrast, other studies
failed to detect mRNAs for Cx26, Cx32, Cx37, Cx40, Cx43 and Cx45,
suggesting that human circulating neutrophils do not express con-
nexins [31,61,62]. However, positive immunodetection of Cx43 was
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[61], suggesting that Toll-like receptor (TLR) activation of neutrophils
may induce the transcription of Cx43. Moreover, in humans, LPS in-
duced the translocation of Cx43 to the membrane of neutrophils and
promoted their aggregation. Aggregated neutrophils exhibited GJIC
only when treated with conditioned medium from activated ECs,
suggesting that soluble factors secreted by these cells may be involved
in the induction of gap junctions in neutrophils during tissue injury
[63]. In contrast to these studies, neutrophils recovered from inﬂamed
lungs after bronchoalveolar lavages did not show Cx43 expression or
cell coupling [62]. Controversies between laboratories regarding GJIC
in neutrophils therefore leave many hypotheses unresolved.
Neutrophil extravasation seems to involve GJIC, since transendothelial
migration of these cells was increased in the presence of connexin-
mimetic peptides or gap junction channel blockers [60,64]. Recently, it
has been proposed that Cx43 in neutrophils may exert anti-
adhesion properties by modulating the endothelium barrier func-
tions [65]. The mechanism underlying such a role appeared to in-
volve hemichannels rather than GJIC. Indeed, this anti-adhesive
effect of Cx43 was explained by the extracellular release of ATP
from these cells via hemichannels, which is similar to the anti-
adhesive effect of Cx37 in monocytes described above [65]. However
in this case, ATP does not act directly on the inﬂammatory cell. Rath-
er, ATP undergoes hydrolysis to adenosine by the action of ecto-
apyrase (CD39) and CD73 at the surface of ECs. Adenosine then acti-
vates its receptors on the EC surface that trigger a cAMP-dependent
intracellular signaling, resulting in the decreased expression of ad-
hesion molecules [65]. Although the latter study did not take into ac-
count changes in endothelial GJIC in response to the ATP/adenosine
ratio, a dysfunctional endothelium may interfere with these protec-
tive mechanisms, which may promote neutrophil recruitment to
atherosclerotic lesions.
2.2.5. Platelets
Platelets are anucleated fragments of bone marrow megakaryo-
cytes that play a major role in inﬂammation, homeostasis and throm-
bus formation after endothelial injury. Upon activation, platelets
undergo morphological changes and express molecules that enhance
their adhesion to the endothelium as well as to other inﬂammatory
cells, including neutrophils [66]. The platelet–neutrophil interaction
plays a pivotal role in acute inﬂammation, and aggregates of both
are increased in patients with CAD [66,67]. Although the causal role
of platelet–neutrophil interaction in atherosclerosis remains to be
elucidated, it may help to explain some of the pathophysiological
events associated with different clinical states [68]. Based on the ra-
tionale of reducing thrombus formation after plaque rupture, anti-
aggregating drugs are widely prescribed, and have shown clear bene-
ﬁts over the last decades. But in addition, therapeutic inhibition of
neutrophil–platelet and platelet–platelet aggregation may prove use-
ful in the stage of atherosclerosis development as well, by moderating
inﬂammation in the vessel wall.
Recently, connexins and GJIC have been shown to contribute to
platelet aggregation by providing an intercellular pathway that nega-
tively regulate thrombus propensity [69] (Fig. 1 top right). In this
study, Angellilo-Scherrer and colleagues report the presence of Cx37
in mouse and human platelets and the intercellular transfer of the
Cx37-permeant gap junction tracer neurobiotin. Neurobiotin transfer
was reduced by gap junction blockers and was abrogated in platelets
isolated from Cx37-deﬁcient mice. Interestingly, bleeding time after
tail transsection was reduced by half in Cx37-deﬁcient mice as com-
pared to wild-type mice. Moreover, thrombus propensity was in-
creased in Cx37-deﬁcient mice both after application of FeCl3 to the
mesenteric arteries and after intravenous injection of collagen and
epinephrine in anesthetized mice. In keeping with these in vivo ob-
servations, in vitro aggregation assays showed increased reactivity
to low-dose agonists of mouse platelets lacking Cx37. Increase inthe extent of platelet aggregation was reproduced when wild-type
mouse or human platelets were treated with pharmacological gap
junction blockers or with a Cx37-mimetic peptide. Thus, it appears
that functional Cx37 gap junction channels moderate platelet
activation.
Although the signals thatmove throughCx37 gap junctions have not
been discovered, the authors further showed that the 1019C>T poly-
morphism of the human Cx37 gene, coding for Cx37-319P or -319S, af-
fected the gap junctional permeability to neurobiotin. In fact, enhanced
intercellular spread of the tracer was observed in cell lines expressing
the Cx37-319S isoform as compared to cells expressing Cx37-319P
channels. Interestingly, platelets from individuals with the latter poly-
morphism (decreased Cx37 channel permeability) showed enhanced
reactivity in in vitro aggregation assays, consistent with the idea that ef-
ﬁcient platelet-to-platelet coupling limits thrombus growth. As men-
tioned above, the Cx37 1019C>T polymorphism strongly associates
with carotid and coronary artery stenosis [11–13,15], and is an indepen-
dent risk factor formyocardial infarction [12,14]. Togetherwith the pre-
vious ﬁnding that Cx37 in monocytes regulates the leukocyte adhesion
to the endothelium [32], the data suggest that impaired Cx37 channel
function may accelerate the development of atherosclerosis.
2.2.6. Mast cells
Mast cells are primarily known as essential effectors in the resolu-
tion of allergic responses. Recent investigations however have now
also implicated mast cells in the initiation and progression of athero-
sclerosis. Mast cells derive from bone marrow cells and circulate in
the peripheral blood as mast cell precursors before being recruited
to speciﬁc tissues and organs where they further mature. Mast cells
also reside in the vessel wall, particularly in perivascular tissue, and
accumulate in atherosclerotic lesions [70,71]. Upon activation by
IgE, complement components or viral or bacterial pathogens, mast
cells acutely release a fraction of their cytoplasmic granules that con-
tain a large panel of mediators including neutral proteases, cathep-
sins, histamine, heparin and several cytokines and growth factors.
The activities of these various mediators have been found to contribute
to the initial fatty streak formation as well as to the destabilization of
plaques, thereby making it prone to rupture [72–74]. In vitro studies
have revealed that mast cells regulate the behavior of atheroma-
associated cell types through their secreted mediators, although oppo-
site results have been obtained depending on the mediator involved.
In fact, histamine and basic ﬁbroblast growth factor (bFGF) released
from mast cells activate SMC surface receptors and accelerate their mi-
gration and proliferation [75,76], whereas mast cell-derived heparin
proteoglycans inhibit proliferation of aortic SMCs in culture [77]. In
this respect, the recent work of Ehrlich and colleagues describing a
role for Cx43-mediated GJIC between mast cells and ﬁbroblasts in
wound repair and ﬁbrosis is of particular interest. Using a sophisticated
co-culture model, they showed that heterocellular GJIC between mast
cells and ﬁbroblasts increases ﬁbroblast proliferation and ﬁbroblast-
induced collagen lattice contraction, two important hypertrophic scar
ﬁbroblast activities [78]. Moreover, heterocellular GJIC between a
mast cell line (RMC-1) and human dermal ﬁbroblasts transformed
these cells into myoﬁbroblasts, expressing α-SM actin within cytoplas-
mic stress ﬁbers [79]. Whether GJIC between mast cells and other cell
types within the atherosclerotic lesion also directs the activities of
these cells remains to be established.
2.3. Smooth muscle cell recruitment
Lesion progression involves the migration of SMCs from the media
into the intima where they proliferate in response to mediators such
as platelet-derived growth factor (PDGF). In the intima, SMCs produce
extracellular matrix macromolecules, including collagen and elastin,
and form a ﬁbrous cap that covers the plaque [2,80]. Progenitor cells
from the blood might also settle as SMCs in the atherosclerotic lesion
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tribute to the extension of the necrotic lipid core. As mentioned
above, the atherosclerotic plaque generally grows silently for years
without producing any clinical symptoms. Large atheroma may cause
clinical manifestations by inducing ﬂow-limiting stenoses. Alternative-
ly, rupture of the plaque's ﬁbrous capmay provoke thrombus formation
that can create an acute ischemia. Paradoxically, plaque rupture does not
often occur at the sites with the most severe narrowing. Rather, patho-
logical observations have shown that ruptured plaques typically have a
thin, collagen-poor ﬁbrous cap with few SMCs but abundant macro-
phages and a large necrotic core [82]. Macrophages in the lesion general-
ly produce enzymes that degrade collagen (matrix metalloproteinases;
(MMPs)) as well as mediators that induce further apoptotic cell death
of SMCs. Hence, the balance and interaction between macrophages and
SMCs is a critical determinant for the progression and stability of ad-
vanced atheroma.
Migration and proliferation of vascular SMCs as well as synthesis
of extracellular matrix by these cells commonly involve phenotypic
transformation of SMCs from the differentiated contractile state to
the activated synthetic state. Connexins appeared to play a crucial
role in phenotypic switch of vascular SMCs. An early study from the
group of Nicolas Severs showed that cytokine-induced modulation
of contractile SMCs to synthetic SMCs coincided with more numerous
and larger gap junctions as well as increased Cx43 expression [83].
Transforming growth factor (TGF)-β-treated human aortic SMCs
also upregulate Cx43 expression which correlates with increased syn-
thetic activity and, paradoxically, enhanced contractile differentiation
[84]. Coronary SMCs show a heterogeneous phenotype, with both
spindle-shaped SMCs (S-SMCs) and rhomboid SMCs (R-SMCs) [85].
R-SMCs display an increased proliferative, migratory, proteolytic phe-
notype and express more Cx43 than S-SMCs. Furthermore, R-SMCs do
not express Cx40, an additional gap junction protein found in S-SMCs.
When S-SMCs are treated with PDGF they acquire a rhomboid pheno-
type, with a concomitant upregulation of Cx43 and a loss of Cx40 and
α-SM actin [86]. Increased Cx43 expression between intimal SMCwas
also observed in vivo in early atherosclerotic lesions in human and
mice [20,87]. Interestingly, these increased Cx43 expression levels be-
tween intimal SMCs declined with progression of the lesion [87]. The
level of Cx43 expression positively correlates with nuclear factor kappa
B (NF-κB) activation in human radial artery, suggesting the involve-
ment of this transcription factor in the regulation of Cx43 expression
in vascular SMCs [88]. Binding of NF-κB to the Cx43 gene promoter
was recently demonstrated in the context of renin-dependent hyper-
tension in murine arteries [89]. The contribution of Cx43 to lesion for-
mation and progression was studied in atherosusceptible LDL receptor
knockout (LDLR−/−) mice in which Cx43 expression was reduced by
half (Cx43+/−) [90]. Cx43+/−LDLR−/− mice displayed reduced plaque
formation but, more impressively, lesions in these mice had thicker ﬁ-
brous caps containing more SMCs and interstitial collagen. In addition,
smaller lipid-cores and fewer macrophages were observed in lesions
of Cx43+/−LDLR−/− mice, whereas leukocyte counts in peripheral
blood were similar to the control group. Thus, targeting Cx43 may
favor potential plaque stabilizing processes rather than affecting plaque
formation alone. The scenario by which reduced Cx43 ultimately leads
to plaque stabilization remains to be identiﬁed, but likely involves addi-
tional functions of Cx43 in macrophages as well [91].
Oxidized phospholipids, the active components of oxLDL, are be-
lieved to promote key changes in vascular SMC phenotype during ath-
erogenesis. The effects on Cx43 expression and phosphorylation of
two oxidized phospholipid derivatives (1-palmitoyl-2-oxovaleroyl-sn-
glycero-3-phosphorylcholine (POVPC) and 1-palmitoyl-2-glutaroyl-
sn-glycero-3-phosphocholine (PGPC)) were therefore compared in
the mouse carotid artery after direct application of the compounds. Ap-
plication of POVPCdecreased Cx43 levels, enhanced its phosphorylation
at serine 279/282 and increased SMC proliferation, whereas PGPC en-
hanced serine 368 phosphorylation with no associated change inproliferation [92]. These intriguing results unmasked that post-
translational modiﬁcations may add an additional level of complexi-
ty to the implication of Cx43 in atherosclerosis.
2.4. Other repair-related mechanisms
2.4.1. Angiogenesis
The formation of microvessels (angiogenesis) has recently re-
ceived increasing attention as a possible contributor to the risk of
plaque rupture. Vasa vasorum, a network of microvasculature origi-
nating primarily in the adventitia of large arteries, become activated
during atherosclerosis in human [93] and mice [94]. Initial observa-
tional studies as early as 1936 already pointed toward the existence
of microvessels in atherosclerotic lesions and their absence from the
intima of healthy arteries [95]. More recent studies have revealed
that microvessel content increases with plaque progression, a pro-
cess that is likely stimulated by plaque hypoxia, ROS and hypoxia-
inducible factor signaling (see for a review: [96]). As such, plaque an-
giogenesis seems to be a physiological response to the diseased state
of the arterial wall rather than a requirement for atherogenesis.
However, plaque microvessels are immature and fragile. This dis-
torted integrity of the microvessel endothelium likely leads to
intraplaque hemorrhage. The associated accumulation of red blood
cell (RBC)-derived cholesterol and rapid expansion of the necrotic
core as well as the inﬂux of macrophages and other cells involved
in RBC and iron phagocytosis places the plaque at increased risk for
rupture [96–98]. Molecular therapies aimed at reducing plaque an-
giogenesis might thus be an attractive novel target to alleviate the
risk of plaque rupture.
The formation of new blood vessels in adults (angiogenesis) in-
volves branching and extension of pre-existing vessels. It may however
also occur via recruitment of endothelial progenitor cells (EPCs) from
the bone marrow [2]. Vascular endothelial growth factor (VEGF) is the
major growth factor involved in these processes. It stimulates the sur-
vival of ECs and increases their proliferation and motility in angiogene-
sis originating from pre-existing vessels. VEGF rapidly and transiently
disrupts GJIC in ECs. This effect has been correlated with changes in
Cx43 phosphorylation [99], thus may likely involve a change in kinetics
of Cx43 gap junction channels. Connexins have been frequently associ-
ated withmigration and proliferation of ECs. Microvascular ECs migrat-
ing from the edges of a mechanically induced wound in culture have
increased Cx43 levels and enhanced Lucifer Yellow dye diffusion com-
pared with cells at distance from the wound [100,101]. Interestingly,
Cx37 expression levels and permeability to Propidium Iodide, a Cx37-
permeant molecule, showed an opposite response from Cx43 upon
wounding of a monolayer bEnd3 cells, a microvascular EC line express-
ing all three endothelial connexins [101]. The requirement for proper
Cx43/Cx37 expression for coordinated migration of ECs has been dem-
onstrated using a chimeric connexin (3243H7) or a fusion protein
(Cx43-βGal) with dominant negative properties [101]. Speciﬁc GJIC
also regulates the formation and complexity of capillary branches in
an in vitro Matrigel angiogenesis assay [102]. Many connexins have
been implicated in the proliferation of various cancer cell types [103],
but Cx37 seems to be the most important growth regulator for ECs. It
suppresses cell proliferation by increasing cell cycle time through an ex-
tension of all phases of the cell cycle and accumulating cells at the G1/S
checkpoint [104] (Fig. 1 bottom right). In agreement with this notion,
Cx37 deletion enhances vascular growth, including angiogenesis, and
facilitates hindlimb recovery after an ischemic insult in mice [105].
Whether Cx37 also affects the formation of newmicrovessels in athero-
sclerotic lesions is at present not known. It is however of interest that
the 1019C>T polymorphism in the Cx37 gene that has been associated
with CAD and MI differentially affects the proliferation of the endothe-
lial SK-HEP-1 cell line [106]. Moreover, this polymorphism has also
been associated with an altered incidence of hemangiosarcoma, a
human endothelium-derived cancer [107].
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Lymphatic vessels have also been detected in human coronary and
carotid atherosclerotic lesions [96]. Similar to blood microvessels,
lymphatic microvessel content increases with plaque progression
[108]. It is presently unknown whether intraplaque lymphatics are
protective or deleterious for plaque progression and rupture. On the
one hand, inadequate lymphangiogenesis in atherosclerotic plaques
may result in inability to drain extravasated RBC, leukocytes and lipo-
proteins, thus sustaining local inﬂammation. On the other hand, re-
duction in lymphatic vessels would result in less efﬁcient draining
plaque leukocytes and cytokines to the lymphatic nodes and lym-
phoid tissues where immune cells may be sensitized and activated.
A role for gap junctions in lymphatic vessels has already been
suggested in 1978 [109], but in spite of numerous studies on GJIC in
cardiovascular system, there has only been limited characterization
in lymphatic vessels or lymphatic ECs [110,111]. Survey microarray
studies comparing lymphatic and blood ECs identiﬁed the expression
of Cx43 and Cx47 in lymphatic ECs [112]. Recent in situ studies re-
vealed the expression of Cx37, Cx43 and Cx47 during mouse lym-
phatic development [113,114]. Interestingly, differential Cx37/Cx43
expression patterns were observed between (future) valve-forming
regions and the lymphangion [114] as well as on upstream and down-
stream sides of lymphatic valves [113]. Lymphatic valve develop-
ment and function are profoundly disturbed in Cx37-deﬁcient mice
[113,114]. Finally, Cx47 expression was only weakly detected in early
lymphatic vessels but became later on highly enriched in a subset of
ECs in lymphatic valves [113]. Intriguing mutations in Cx47 gene have
been recently linked to a subset of human hereditary lymphedemas,
although the nature of lymphatic vascular defect or molecular mecha-
nism is at present unknown [115,116]. Although these recent studies
point toward a role for connexins in physiological development of lym-
phatics, no studies have been published so far that evaluate the role of
connexins in lymphatic vascular function in disease.
3. Conclusions and perspectives
In summary, three connexins in several subtypes have been di-
rectly implicated in the development of atherosclerosis. These are
Cx37 in monocytes and platelets, Cx40 in the endothelium, and
Cx43 in SMCs. However numerous other cell types that play a role
in atherosclerosis also express one (or more) of these connexins. As
described in this review, a function could generally be ascribed to a
connexin expressed by each cell type. It thus seems very likely that
future studies will be able to ﬁnd other implications for connexins
in atherosclerosis development.
It is increasingly evident that connexins are generally not expressed
by a single cell type, and that they may have distinct or even opposite
roles depending on the cell type studied. Thus, the association between
one connexin and a complex disease like atherosclerosis is not straight-
forward. A genetic polymorphism in a connexin genemayhavemultiple
additive or counteracting effects on disease development. This high-
lights the need for cell-speciﬁc connexin knock-out models to detangle
the complicated network of connexin implications in atherosclerosis.
Another recurrent question is whether the results obtained in
mouse models can be applied to humans. Although mouse models
closely mimic human pathology, there are important differences.
For instance, plaque rupture with superimposed thrombosis, the
most common complication of human atherosclerosis, is rarely ob-
served in mice. Consequently, clinical events such as myocardial in-
farction or ischemic stroke are almost never seen in these models.
Moreover, the small size of mice excludes research in interventional
cardiology and diagnostic imaging. Although these problems general-
ly apply to atherosclerosis research, they will hinder further develop-
ments toward connexin-based therapies and await the development
of new animal models as well as of minimally-invasive methods
that would enable to conﬁrm the results in humans.Acknowledgements
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